We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ARUP Labs, UH Case Medical Center Sign Distribution Agreement for Novel HIV Test
News

ARUP Labs, UH Case Medical Center Sign Distribution Agreement for Novel HIV Test

ARUP Labs, UH Case Medical Center Sign Distribution Agreement for Novel HIV Test
News

ARUP Labs, UH Case Medical Center Sign Distribution Agreement for Novel HIV Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ARUP Labs, UH Case Medical Center Sign Distribution Agreement for Novel HIV Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

University Hospitals Case Medical Center has signed an agreement with ARUP Laboratories, a major national clinical reference laboratory that offers an extensive menu of highly complex and unique medical tests to hospitals, medical schools, and other nonprofit and commercial organizations throughout the United States. 

Under the agreement, ARUP will include in its menu of tests an HIV diagnostic test invented at University Hospitals’ Translational Laboratory by Miguel Quinones-Mateu, PhD, scientific director at the UH lab and assistant professor at the Department of Pathology, Case Western Reserve University School of Medicine. 

The novel test, DEEPGEN™HIV, monitors the success of anti-HIV treatment by determining drug resistance and the ability of the virus to infect different cells based on deep genetic sequencing. ARUP, a nonprofit enterprise of the University of Utah, will include DEEPGEN in its menu of tests and will nationally market the assay. Clinical samples will then be referred to UH Translational Laboratory (UHTL, www.uhtl.org) in Cleveland from all 50 states. 

DEEPGEN™HIV provides a sensitive platform for HIV physicians and researchers, both in the academia and industry. The assay allows the detection of minority variants at frequencies unimaginable with current HIV genotypic tests based on standard (Sanger) sequencing. 

“Although the clinical relevance of these minority members of the viral population is still under debate, it is reasonable to assume that the earlier these mutant viruses are detected, the sooner the proper strategy can be defined to control their growth,” said Dr. Quiñones-Mateu. “DEEPGEN™HIV is now the primary HIV genotyping assay used by HIV physicians at the Case Western Reserve University/University Hospitals AIDS Clinical Trials Unit, and we have been analyzing clinical specimens from other institutions around the region. This agreement with ARUP will expedite the use of this innovative and highly sensitive assay nationwide, which will allow us to enhance the care and treatment of HIV-infected individuals across the country.” 

“I am excited about our relationship with ARUP, as it appears to be a natural synergy that we both may leverage to expand the quality of diagnostic testing and care provided to patients with HIV nationally,” said Ronald E. Dziedzicki, chief operating officer at UH Case Medical Center. 

“Our relationship with UH Case Medical Center enables ARUP to offer this innovative test to our clients for the management of patients with HIV,” said Jerry Hossong, MD, DDS, ARUP’s chief medical officer and director of laboratories. “We are very pleased to include this test as part of our comprehensive menu of services.”

Advertisement